Archives
G-1 (CAS 881639-98-1): Selective GPR30 Agonist Evidence & Pr
G-1 (CAS 881639-98-1): Selective GPR30 Agonist Evidence & Protocols
Executive Summary: G-1 (CAS 881639-98-1) is a highly selective agonist of GPR30/GPER1, exhibiting a binding affinity (Ki) of approximately 11 nM for GPR30 and negligible activity toward classical estrogen receptors ERα and ERβ even at micromolar concentrations (source: product_spec). G-1 mediates robust elevation of intracellular calcium (EC50 = 2 nM) and PI3K-dependent nuclear PIP3 accumulation in vitro (source: product_spec). The compound inhibits migration of breast cancer cell lines SKBr3 (IC50 = 0.7 nM) and MCF7 (IC50 = 1.6 nM) (source: product_spec). In vivo, chronic G-1 administration improves cardiac function and reduces fibrosis in heart failure models (source: product_spec). Recent studies confirm G-1's immunomodulatory impact via GPR30 in trauma-induced inflammation (source: Peng Wang et al., 2021).
Biological Rationale
G protein-coupled estrogen receptor 30 (GPR30/GPER1) mediates rapid, non-genomic estrogen signaling in diverse physiological contexts, distinct from classical nuclear estrogen receptor pathways. GPR30 is predominantly localized in the endoplasmic reticulum and plasma membrane, where it binds estradiol and synthetic ligands such as G-1 to trigger intracellular signaling cascades (source: Peng Wang et al., 2021). Selective activation of GPR30 has been implicated in cardiovascular homeostasis, immune cell regulation, and cancer cell migration, providing a rationale for using G-1 to dissect non-classical estrogen effects.
Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist
G-1 is a non-steroidal small molecule that binds GPR30/GPER1 with high selectivity (Ki ≈ 11 nM), displaying negligible affinity for ERα or ERβ at concentrations up to 10 μM (source: product_spec). Upon receptor engagement, G-1 induces rapid elevation of intracellular Ca2+ (EC50 = 2 nM), stimulates PI3K/AKT signaling, and promotes nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (source: product_spec). These effects culminate in modulation of cellular proliferation, migration, and immune responses. In immune models, G-1 restores CD4+ T lymphocyte function after traumatic insult by attenuating endoplasmic reticulum stress (source: Peng Wang et al., 2021).
Evidence & Benchmarks
- G-1 binds to GPR30/GPER1 with a Ki of ~11 nM, exhibiting over 1000-fold selectivity versus ERα/ERβ (source: product_spec).
- Induces a dose-dependent increase in intracellular Ca2+ in GPR30-expressing cells (EC50 = 2 nM) (source: product_spec).
- Inhibits migration of SKBr3 (IC50 = 0.7 nM) and MCF7 (IC50 = 1.6 nM) breast cancer cells in vitro (source: product_spec).
- Chronic G-1 administration (120 μg/kg, 14 days) in ovariectomized, heart failure female rats reduces brain natriuretic peptide, suppresses cardiac fibrosis, and normalizes β-adrenergic receptor expression (source: product_spec).
- G-1 reverses trauma-induced CD4+ T cell dysfunction by suppressing endoplasmic reticulum stress in rodent models (source: Peng Wang et al., 2021).
This article extends mechanistic and protocol depth compared to 'Unveiling GPR30 Signaling in Cardiovascular Research' by providing explicit benchmarks and protocol parameters for G-1 use in both cardiovascular and breast cancer models.
For hands-on troubleshooting and experimental optimization workflows, see 'G-1 Selective GPR30 Agonist: Applied Workflows and Troubleshooting'; the present article emphasizes numerical potency, selectivity, and in vivo validation data.
Applications, Limits & Misconceptions
G-1 is validated as a tool for dissecting GPR30-mediated signaling in cardiovascular, oncology, and immunological models. It is not suitable for studies targeting classical estrogen receptors, as its affinity for ERα/ERβ is negligible (source: product_spec). Cardiovascular research demonstrates G-1's capability to attenuate cardiac fibrosis and improve contractile function in heart failure models (source: product_spec). In oncology, G-1 consistently blocks migration of breast cancer cell lines at nanomolar concentrations. Immunologically, G-1 restores CD4+ T cell proliferation following trauma by modulating ER stress (source: Peng Wang et al., 2021).
Common Pitfalls or Misconceptions
- G-1 does not activate classical nuclear estrogen receptors (ERα, ERβ) at working concentrations; thus, it cannot be used as a pan-estrogen mimic (source: product_spec).
- G-1 is insoluble in water and ethanol; use DMSO for stock solution preparation (source: product_spec).
- Stock solutions degrade upon prolonged storage at room temperature; store at -20°C and use promptly (source: product_spec).
- In vivo efficacy shown primarily in rodent models; translational limits to human systems should be considered (source: Peng Wang et al., 2021).
- G-1 is not intended for diagnostic or therapeutic use in humans or animals (source: product_spec).
Workflow Integration & Parameters
Protocol Parameters
- binding assay | Ki ≈ 11 nM | GPR30/GPER1 binding | Quantifies selectivity; enables discrimination from ERα/ERβ | product_spec
- calcium mobilization | EC50 = 2 nM | GPR30-expressing cells | Assesses functional agonism at low nanomolar range | product_spec
- cell migration inhibition | IC50 = 0.7 nM (SKBr3), 1.6 nM (MCF7) | In vitro breast cancer lines | Validates anti-migratory efficacy in oncology workflows | product_spec
- in vivo administration | 120 μg/kg/day × 14 days (rat) | Heart failure, ovariectomized female Sprague-Dawley rats | Benchmarks dosing and duration for cardiac endpoints | product_spec
- stock solution prep | ≥10 mM in DMSO, warming & sonication recommended | All experimental workflows | Optimizes solubility for accurate dosing | workflow_recommendation
- storage condition | -20°C, minimize freeze-thaw cycles | Long-term reagent integrity | Prevents compound degradation | workflow_recommendation
For advanced troubleshooting and protocol optimization, see 'G-1 Selective GPR30 Agonist: Applied Workflows and Troubleshooting', which provides hands-on workflow decision trees not detailed here.
Conclusion & Outlook
G-1 (CAS 881639-98-1), as supplied by APExBIO, is a rigorously validated, selective GPR30 agonist for dissecting non-classical estrogen signaling in cardiovascular, oncology, and immunomodulatory research. Its nanomolar potency and minimal off-target activity make it a preferred tool for probing GPR30-specific pathways. Current evidence supports its use in animal models, with clear translational potential yet unproven in human clinical application (source: Peng Wang et al., 2021). For detailed mechanistic context and translational strategy, readers may consult 'Strategic Advances with G-1: GPR30 Agonism in Translational Research', which this article updates by integrating peer-reviewed numeric benchmarks and protocol recommendations.
For product information, specifications, and ordering, see G-1 (CAS 881639-98-1), a selective GPR30 agonist.